ANI Pharma (ANIP) Reports Q4 EPS of 84c

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.84, may not compare to the analyst estimate of $1.09. Revenue for the quarter came in at $38.2 million versus the consensus estimate of $40.71 million.

GUIDANCE:

ANI Pharma sees FY2017 EPS of $3.58-$3.94. ANI Pharma sees FY2017 revenue of $181-190 million.

(Street sees FY EPS of $4.44 on revenue of $177. Estimates may not compare).

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Gorilla Technology raises Q2 2026 revenue outlook to $44M
• Tesla Q2 deliveries: What to expect from the critical report